Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor,...
Covered in this story
What has happened since
- Lilly (Eli) is up 12.3% since this was published, 18 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Lilly (Eli)
- Cantor Fitzgerald: $1.19k → $1.44k by Oct 2027 · Overweight via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LLY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lilly (Eli) →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.